Lack of survival improvement in patients with peripheral T-cell lymphoma

A Surveillance, Epidemiology, and End Results analysis

Daniel Morgensztern, Gail R. Walker, Leonidas G. Koniaris, Izidore Lossos

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In patients with aggressive non-Hodgkin lymphomas (NHLs), T-cell lymphoma (TCL) confers a poor prognosis. Since rituximab has increased survival for patients with diffuse large B-cell lymphoma (DLBCL), we hypothesized that the difference in outcome by phenotype became more pronounced recently and evaluated these changes using the Surveillance, Epidemiology, and End Results (SEER) Program. Cases diagnosed in 1992-1997 (era 1) and 1998-2003 (era 2) were evaluated for outcomes according to immunophenotype and era. A total of 22 252 patients with DLBCL and 2222 with TCL were included. In both eras, patients with TCL were more likely to die from their disease than those with DLBCL. Death from NHL decreased significantly from era 1 to era 2 for all DLBCL patients grouped by age and stage but in none of the TCL groups. Improved outcomes for DLBCL after the introduction of rituximab-based therapies in 1997 have no counterpart in patients with TCL, pointing to the need for new therapies to treat TCL.

Original languageEnglish
Pages (from-to)194-204
Number of pages11
JournalLeukemia and Lymphoma
Volume52
Issue number2
DOIs
StatePublished - Feb 1 2011

Fingerprint

Peripheral T-Cell Lymphoma
T-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Epidemiology
Survival
Non-Hodgkin's Lymphoma
SEER Program
Phenotype
Therapeutics

Keywords

  • Diffuse large B-cell lymphoma
  • SEER
  • T-cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Lack of survival improvement in patients with peripheral T-cell lymphoma : A Surveillance, Epidemiology, and End Results analysis. / Morgensztern, Daniel; Walker, Gail R.; Koniaris, Leonidas G.; Lossos, Izidore.

In: Leukemia and Lymphoma, Vol. 52, No. 2, 01.02.2011, p. 194-204.

Research output: Contribution to journalArticle

@article{d1266f76d68641558227ff483cd20b36,
title = "Lack of survival improvement in patients with peripheral T-cell lymphoma: A Surveillance, Epidemiology, and End Results analysis",
abstract = "In patients with aggressive non-Hodgkin lymphomas (NHLs), T-cell lymphoma (TCL) confers a poor prognosis. Since rituximab has increased survival for patients with diffuse large B-cell lymphoma (DLBCL), we hypothesized that the difference in outcome by phenotype became more pronounced recently and evaluated these changes using the Surveillance, Epidemiology, and End Results (SEER) Program. Cases diagnosed in 1992-1997 (era 1) and 1998-2003 (era 2) were evaluated for outcomes according to immunophenotype and era. A total of 22 252 patients with DLBCL and 2222 with TCL were included. In both eras, patients with TCL were more likely to die from their disease than those with DLBCL. Death from NHL decreased significantly from era 1 to era 2 for all DLBCL patients grouped by age and stage but in none of the TCL groups. Improved outcomes for DLBCL after the introduction of rituximab-based therapies in 1997 have no counterpart in patients with TCL, pointing to the need for new therapies to treat TCL.",
keywords = "Diffuse large B-cell lymphoma, SEER, T-cell lymphoma",
author = "Daniel Morgensztern and Walker, {Gail R.} and Koniaris, {Leonidas G.} and Izidore Lossos",
year = "2011",
month = "2",
day = "1",
doi = "10.3109/10428194.2010.542596",
language = "English",
volume = "52",
pages = "194--204",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Lack of survival improvement in patients with peripheral T-cell lymphoma

T2 - A Surveillance, Epidemiology, and End Results analysis

AU - Morgensztern, Daniel

AU - Walker, Gail R.

AU - Koniaris, Leonidas G.

AU - Lossos, Izidore

PY - 2011/2/1

Y1 - 2011/2/1

N2 - In patients with aggressive non-Hodgkin lymphomas (NHLs), T-cell lymphoma (TCL) confers a poor prognosis. Since rituximab has increased survival for patients with diffuse large B-cell lymphoma (DLBCL), we hypothesized that the difference in outcome by phenotype became more pronounced recently and evaluated these changes using the Surveillance, Epidemiology, and End Results (SEER) Program. Cases diagnosed in 1992-1997 (era 1) and 1998-2003 (era 2) were evaluated for outcomes according to immunophenotype and era. A total of 22 252 patients with DLBCL and 2222 with TCL were included. In both eras, patients with TCL were more likely to die from their disease than those with DLBCL. Death from NHL decreased significantly from era 1 to era 2 for all DLBCL patients grouped by age and stage but in none of the TCL groups. Improved outcomes for DLBCL after the introduction of rituximab-based therapies in 1997 have no counterpart in patients with TCL, pointing to the need for new therapies to treat TCL.

AB - In patients with aggressive non-Hodgkin lymphomas (NHLs), T-cell lymphoma (TCL) confers a poor prognosis. Since rituximab has increased survival for patients with diffuse large B-cell lymphoma (DLBCL), we hypothesized that the difference in outcome by phenotype became more pronounced recently and evaluated these changes using the Surveillance, Epidemiology, and End Results (SEER) Program. Cases diagnosed in 1992-1997 (era 1) and 1998-2003 (era 2) were evaluated for outcomes according to immunophenotype and era. A total of 22 252 patients with DLBCL and 2222 with TCL were included. In both eras, patients with TCL were more likely to die from their disease than those with DLBCL. Death from NHL decreased significantly from era 1 to era 2 for all DLBCL patients grouped by age and stage but in none of the TCL groups. Improved outcomes for DLBCL after the introduction of rituximab-based therapies in 1997 have no counterpart in patients with TCL, pointing to the need for new therapies to treat TCL.

KW - Diffuse large B-cell lymphoma

KW - SEER

KW - T-cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=79551631846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551631846&partnerID=8YFLogxK

U2 - 10.3109/10428194.2010.542596

DO - 10.3109/10428194.2010.542596

M3 - Article

VL - 52

SP - 194

EP - 204

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -